These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 20153225)

  • 1. Why pyridine containing pyrido[2,3-d]pyrimidin-7-ones selectively inhibit CDK4 than CDK2: insights from molecular dynamics simulation.
    Mascarenhas NM; Bhattacharyya D; Ghoshal N
    J Mol Graph Model; 2010 Apr; 28(7):695-706. PubMed ID: 20153225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural requirements of pyrido[2,3-d]pyrimidin-7-one as CDK4/D inhibitors: 2D autocorrelation, CoMFA and CoMSIA analyses.
    Caballero J; Fernández M; González-Nilo FD
    Bioorg Med Chem; 2008 Jun; 16(11):6103-15. PubMed ID: 18468903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
    Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity.
    Dessalew N; Bharatam PV
    Eur J Med Chem; 2007 Jul; 42(7):1014-27. PubMed ID: 17335939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors.
    Singh SK; Dessalew N; Bharatam PV
    Eur J Med Chem; 2006 Nov; 41(11):1310-9. PubMed ID: 16890327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6.
    Liang JD; Zhang YE; Qin F; Chen WN; Jiang WM; Fang Z; Liang XL; Zhang Q; Li J
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):302. PubMed ID: 38856753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
    Ibrahim DA; Ismail NS
    Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
    McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
    Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined ligand and structure based approaches for narrowing on the essential physicochemical characteristics for CDK4 inhibition.
    Mascarenhas NM; Ghoshal N
    J Chem Inf Model; 2008 Jul; 48(7):1325-36. PubMed ID: 18564835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational study of the interactions between guanine derivatives and cyclin-dependent kinase 2 (CDK2) by CoMFA and QM/MM.
    Alzate-Morales J; Caballero J
    J Chem Inf Model; 2010 Jan; 50(1):110-22. PubMed ID: 20030297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of a ligand complexed with Cdk2/Cdk4 by computer simulation.
    Jiang Y; Zou J; Gui C
    J Mol Model; 2005 Nov; 11(6):509-15. PubMed ID: 15928920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity.
    Pratt DJ; Bentley J; Jewsbury P; Boyle FT; Endicott JA; Noble ME
    J Med Chem; 2006 Sep; 49(18):5470-7. PubMed ID: 16942020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
    Chohan TA; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of the surface interaction properties of the binding sites of CDK2, CDK4, and ERK2.
    Kelly MD; Mancera RL
    ChemMedChem; 2006 Mar; 1(3):366-75. PubMed ID: 16892371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-(Phenylaminomethylene)isoquinoline-1,3(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4).
    Tsou HR; Otteng M; Tran T; Floyd MB; Reich M; Birnberg G; Kutterer K; Ayral-Kaloustian S; Ravi M; Nilakantan R; Grillo M; McGinnis JP; Rabindran SK
    J Med Chem; 2008 Jun; 51(12):3507-25. PubMed ID: 18494457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin.
    Aubry C; Wilson AJ; Jenkins PR; Mahale S; Chaudhuri B; Maréchal JD; Sutcliffe MJ
    Org Biomol Chem; 2006 Mar; 4(5):787-801. PubMed ID: 16493461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cyclin D1/cyclin-dependent kinase 4 binding site within the C domain of the retinoblastoma protein.
    Pan W; Cox S; Hoess RH; Grafström RH
    Cancer Res; 2001 Apr; 61(7):2885-91. PubMed ID: 11306463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein structures in virtual screening: a case study with CDK2.
    Thomas MP; McInnes C; Fischer PM
    J Med Chem; 2006 Jan; 49(1):92-104. PubMed ID: 16392795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 4-(benzylaminomethylene)isoquinoline-1,3-(2H,4H)-diones and 4-[(pyridylmethyl)aminomethylene]isoquinoline-1,3-(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4.
    Tsou HR; Liu X; Birnberg G; Kaplan J; Otteng M; Tran T; Kutterer K; Tang Z; Suayan R; Zask A; Ravi M; Bretz A; Grillo M; McGinnis JP; Rabindran SK; Ayral-Kaloustian S; Mansour TS
    J Med Chem; 2009 Apr; 52(8):2289-310. PubMed ID: 19317452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.